Third View Private Wealth Boosts Regeneron Pharmaceuticals Stake

Institutional investor adds over 7,000 shares of biotech giant in Q4

Apr. 14, 2026 at 10:51am

Got story updates? Submit your updates here. ›

An extreme close-up of complex, high-tech biotech equipment and machinery, conveying the advanced scientific capabilities that drive Regeneron's innovative drug development.Regeneron's state-of-the-art research and production facilities power the company's pipeline of groundbreaking biologic therapies.Tarrytown Today

Third View Private Wealth LLC, a private wealth management firm, acquired a new stake of 7,149 shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter, according to a recent 13F filing with the Securities and Exchange Commission. The new position is valued at approximately $5.5 million, making Regeneron the 28th largest holding in Third View's investment portfolio.

Why it matters

Regeneron is a leading biopharmaceutical company known for its innovative drug discovery technologies and blockbuster therapies. The addition of a significant new stake by Third View Private Wealth, a respected institutional investor, signals continued confidence in Regeneron's long-term growth potential within the healthcare sector.

The details

According to the 13F filing, Third View Private Wealth acquired 7,149 shares of Regeneron Pharmaceuticals in Q4 2025. This new position represents 0.7% of the firm's total investment portfolio. Regeneron is known for developing groundbreaking medicines across a range of therapeutic areas including oncology, immunology, ophthalmology and cardiovascular disease.

  • Third View Private Wealth filed the 13F disclosure for Q4 2025 on April 14, 2026.

The players

Third View Private Wealth LLC

A private wealth management firm that acquired a new stake in Regeneron Pharmaceuticals in Q4 2025.

Regeneron Pharmaceuticals, Inc.

A leading U.S. biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

The addition of a significant new stake in Regeneron Pharmaceuticals by Third View Private Wealth underscores the firm's strong growth prospects and leadership position in the biopharmaceutical industry. As Regeneron continues to advance its innovative drug pipeline, institutional investors are taking notice of the company's long-term value.